# AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

> **NCT04617821** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 300 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Cancer
- Locally Advanced Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Nab paclitaxel plus gemcitabine
- **DRUG:** mFOLFIRINOX

## Key facts

- **NCT ID:** NCT04617821
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617821, "AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04617821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*